Anthony Vigliotti, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1372 State Route 5, Chittenango Healthcare Center, Chittenango, NY 13037 Phone: 315-687-5100 Fax: 315-687-0252 |
Tammy Farr, FNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 153 W Genesee St, Chittenango, NY 13037 Phone: 315-778-1216 |
Dr. Thomas V Chmelicek, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 153 W Genesee St, Chittenango, NY 13037 Phone: 315-687-5100 Fax: 315-687-0252 |
Erika C Lambert, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 304 Genesee Street, Chittenango, NY 13037 Phone: 315-687-6467 Fax: 315-251-2240 |
Dr. Diane Sophia Ojugbeli, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 304 Genesee St, Chittenango, NY 13037 Phone: 315-687-6467 Fax: 315-687-6041 |
Dr. Kristina M. Tervo, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 153 W Genesee St, Chittenango, NY 13037 Phone: 315-687-5100 Fax: 315-687-0252 |
Dr. Joyce Tibbett, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 153 W Genesee St, Chittenango, NY 13037 Phone: 315-687-5100 Fax: 315-687-0252 |
News Archive
The Gladstone Institutes will receive funds totaling $5.6 million over five years as part of the first-ever major funding initiative focusing on HIV eradication.
eClinicalWorks, a market leader in ambulatory clinical systems, today announced that Women's Care Florida, one of the largest independent, fully integrated OB/GYN groups in the United States, has chosen the eClinicalWorks comprehensive electronic health records (EHR) solution for its 165 providers across 52 locations.
Two in 10 young people in South East Spain have poor sperm density, which involves requiring more time to accomplish fertilization. The most common means of exposure to pesticides is food and other household products.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the first patient has been dosed in Japan in a Nippon Kayaku sponsored Phase 1 study of apaziquone in bladder cancer.
› Verified 5 days ago